http://rdf.ncbi.nlm.nih.gov/pubchem/patent/CA-2307632-C

Outgoing Links

Predicate Object
assignee http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_cac023d2e2874224ecbbcccbdea1fc91
http://rdf.ncbi.nlm.nih.gov/pubchem/patentassignee/MD5_b9fa13c33b79ba86e25d61d5e3cee4f2
classificationCPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0043
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K9-0048
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/C07D215-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P27-16
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K47-183
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-495
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61K31-496
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-02
http://rdf.ncbi.nlm.nih.gov/pubchem/patentcpc/A61P31-04
classificationIPCInventive http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K47-18
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/C07D215-56
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-08
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K9-00
http://rdf.ncbi.nlm.nih.gov/pubchem/patentipc/A61K31-496
filingDate 1999-08-20-04:00^^<http://www.w3.org/2001/XMLSchema#date>
grantDate 2007-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
inventor http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_3dc7ba3a8d7cc6f1721e25ba39cdc213
http://rdf.ncbi.nlm.nih.gov/pubchem/patentinventor/MD5_0eaf477daded3b698fb7b7092cbfb8f7
publicationDate 2007-05-22-04:00^^<http://www.w3.org/2001/XMLSchema#date>
publicationNumber CA-2307632-C
titleOfInvention Aqueous liquid pharmaceutical composition
abstract There is provided an aqueous liquid pharmaceutical composition which comprises Gatifloxacin (chemical nomenclature: (~)-1-cyclopropyl-6-fluoro-1,4-dihydro-8-methoxy-7-(3-methyl-1-piperazinyl)-4-oxo-3-quinoline carboxylic acid) or its salt and disodium edetate. Further, there are provided a method for raising corneal permeability of Gatifloxacin, a method for preventing precipitation of Gatifloxacin crystals, and a method for preventing coloration of Gatifloxacin by incorporating disodium edetate into an aqueous liquid preparation containing Gatifloxacin or its salt.
priorityDate 1998-08-21-04:00^^<http://www.w3.org/2001/XMLSchema#date>
type http://data.epo.org/linked-data/def/patent/Publication

Incoming Links

Predicate Subject
isDiscussedBy http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6144
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419481172
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID6038
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID425188129
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID54675830
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454515022
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID8759
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419502792
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID5379
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID419587381
http://rdf.ncbi.nlm.nih.gov/pubchem/compound/CID29089
http://rdf.ncbi.nlm.nih.gov/pubchem/substance/SID454429464

Total number of triples: 39.